Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM4BZEJ)

Drug Name

BMS-986118 Drug Info

Synonyms

CHEMBL4080226; 1610562-74-7; 2-((4S,5S)-1-(4-(((3R,4R)-1-(5-chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl)oxy)phenyl)-4-methyl-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-5-yl)acetic acid; SCHEMBL15710831; BDBM50243975; 2-[(3S,4S)-2-[4-[(3R,4R)-1-(5-chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl]oxyphenyl]-4-methyl-5-(trifluoromethyl)-3,4-dihydropyrazol-3-yl]acetic acid

Indication

Disease Entry	ICD 11	Status	REF
Type 2 diabetes	5A11	Preclinical	[1]

Cross-matching ID

PubChem CID: 76900387
TTD Drug ID: DM4BZEJ

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Free fatty acid receptor 1 (GPR40)	TTB8FUC	FFAR1_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification

05 Endocrine, nutritional or metabolic disease

Disease Class

ICD-11: 5A11 Type 2 diabetes mellitus

The Studied Tissue

Liver tissue

The Studied Disease

Type 2 diabetes [ICD-11:5A11]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Free fatty acid receptor 1 (GPR40)	DTT	FFAR1	6.14E-01	-0.08	-1.33

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opin Investig Drugs. 2016 Aug;25(8):871-90.
2	Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists. J Med Chem. 2018 Feb 8;61(3):681-694.